Most side effects of GLP-1 receptor agonists (semaglutide, sold as Ozempic and Wegovy; tirzepatide, sold as Mounjaro and Zepbound) are mild, dose-related, and temporary — but a short list of symptoms means seek care now. Serious problems are uncommon: a Harvard and CDC analysis found emergency-department visits attributable to semaglutide were rare — fewer than about 4 per 1,000 patients, and mostly gastrointestinal. The point of this page is to help you tell normal and temporary from call someone now. The symptoms that can't wait: severe stomach pain radiating to your back with vomiting (pancreatitis); swelling of the face or throat or trouble breathing (allergic reaction — call emergency services); and severe vomiting with no gas or stool and a hard, bloated belly (a possible bowel obstruction). General information, not medical advice; if this is an emergency, call your local emergency number.
The red flags, one by one
Each of these is drawn from the FDA label and patient-facing clinical sources. For most people none of them will happen — but knowing the symptom and why it matters lets you act fast if one does.
A new neck lump, persistent hoarseness, or trouble swallowing — thyroid C-cell tumors. This is the FDA Boxed Warning for this class. The concern comes from thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rodents; whether the same risk applies to humans is not known. These medicines are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Report a new neck mass, lasting hoarseness, or trouble swallowing or breathing to your prescriber or a specialist promptly.
Severe stomach pain that bores through to your back — acute pancreatitis. The pain is severe, often radiates to the back, can be worse after eating, and comes with persistent nausea or vomiting. This needs emergency evaluation.
Severe upper-right belly pain with fever or jaundice — gallbladder disease. Gallstones and gallbladder inflammation can cause severe pain in the upper-right abdomen, fever, nausea or vomiting, and yellowing of the skin or eyes. Rapid weight loss raises the risk; see our gallbladder page for the full picture and symptoms to watch.
Severe persistent vomiting with no gas or stool and a hard, swollen belly — obstruction or severe slowed emptying. These medicines slow how fast the stomach empties by design, which is usually just uncomfortable. But severe persistent vomiting, an inability to pass gas or stool, and severe bloating with a hard, distended belly can signal gastroparesis, ileus, or a bowel obstruction. An obstruction is a surgical emergency. Ileus and intestinal obstruction were added to the labeling in postmarketing reports in September 2023; how often they occur is not quantified.
Unrelenting vomiting or diarrhea with intense thirst and dizziness — severe dehydration. Watch for vomiting or diarrhea that won't let up, intense thirst, dry mouth, dizziness, and dark or scant urine. Severe dehydration is the engine behind the next red flag.
A marked drop in urine output, or swelling of the ankles, hands, or feet — acute kidney injury. The FDA notes that kidney injury with these medicines has occurred mostly in patients who became dehydrated from nausea, vomiting, or diarrhea. A sharp decrease in how much you're urinating, or new swelling, warrants same-day evaluation.
Swelling of the lips, tongue, or throat, trouble breathing, or widespread hives — serious allergic reaction. Angioedema and anaphylaxis can cause swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, widespread hives, or fainting. This is a call-emergency-services situation, not a wait-and-see one.
Shakiness, sweating, confusion, or slurred speech — severe low blood sugar. A GLP-1 on its own rarely causes low blood sugar, but the risk rises sharply when it's combined with insulin or a sulfonylurea. Early signs include shakiness, sweating, confusion, blurred vision, and slurred speech; severe lows can progress to seizures or loss of consciousness, which is an emergency.
Any change in your vision — worsening diabetic retinopathy. For people taking semaglutide for type 2 diabetes, the label notes a signal for worsening diabetic retinopathy: in the SUSTAIN-6 trial, retinopathy complications occurred in 3.0% of patients versus 1.8% on placebo, concentrated in people who already had retinopathy and whose blood sugar dropped rapidly. This is a diabetes-population, semaglutide-specific signal — not a general weight-loss warning, and not established the same way for tirzepatide. Report any vision change promptly.
New or worsening suicidal thoughts or mood changes — report immediately. Here the regulatory picture is changing and we want to be honest about it. After reviewing the question, the FDA did not find evidence of a causal link between these medicines and suicidal behavior or ideation, and on January 13, 2026 it requested removal of that warning from GLP-1 labeling. That said, your mental health still matters and reactions vary: if you notice new or worsening mood changes or suicidal thoughts, report them right away regardless. In the US you can call or text 988 for the Suicide and Crisis Lifeline, or call emergency services if you are in crisis.
What to do: a quick triage guide
If you're not sure how urgent something is, this is the rule of thumb. When in doubt about a severe symptom, err toward the higher tier — this is standard emergency-triage guidance, not a substitute for clinical judgment.
Call emergency services (911 in the US) now if you have:
- Trouble breathing, or swelling of the face or throat (a possible allergic reaction).
- Fainting, a seizure, or someone who can't be woken (a possible severe low blood sugar).
- Severe, unrelenting abdominal pain with vomiting (a possible pancreatitis or bowel obstruction).
Seek urgent, same-day care if you have:
- Severe upper-right belly pain with fever or jaundice (a possible gallbladder problem).
- Persistent vomiting with no gas or stool and a bloated belly (a possible obstruction).
- Severe dehydration, or a sharp drop in how much you're urinating.
Call your prescriber right away if you have:
- A new neck lump, persistent hoarseness, or trouble swallowing.
- Any new change in your vision.
- New or worsening mood changes or suicidal thoughts — or call 988 or emergency services if you are in crisis.
- Persistent vomiting or diarrhea, before it becomes severe.
Most people on a GLP-1 never face any of this. The common side effects — nausea, diarrhea, and the like — are usually mild and fade as your body adjusts; you can read more about the everyday side effects and how long they tend to last. Knowing the red flags is simply so that, on the rare day one appears, you already know what to do.
Frequently asked questions
What GLP-1 symptoms are a medical emergency? Call emergency services for trouble breathing or swelling of the face or throat (a possible allergic reaction), fainting or a seizure (a possible severe low blood sugar), or severe unrelenting stomach pain with vomiting (a possible pancreatitis or bowel obstruction). These are not manage-at-home situations.
Is stomach pain on a GLP-1 ever serious? Usually it's just slowed digestion, but severe pain that radiates to the back with persistent vomiting can signal pancreatitis, and severe pain with no gas or stool and a hard, bloated belly can signal an obstruction. Both need prompt evaluation.
Is there still a suicidal-thoughts warning on GLP-1 labels? This is actively changing. After review, the FDA did not find an increased risk and on January 13, 2026 requested removal of the suicidal-behavior and ideation warning from GLP-1 labeling. Even so, report any new or worsening mood changes or suicidal thoughts to your prescriber right away, or call 988 or emergency services if you are in crisis.
Do these warnings apply to both semaglutide and tirzepatide? Most class warnings — the thyroid Boxed Warning, pancreatitis, gallbladder, and slowed-emptying concerns — apply across GLP-1 receptor agonists. The worsening-retinopathy signal is specific to semaglutide in people with type 2 diabetes and is not established the same way for tirzepatide.
How we reviewed this: written from authoritative sources, including the FDA label via DailyMed (Boxed Warning and Warnings and Precautions), the FDA Drug Safety Communication on the suicidal-ideation warning, Cleveland Clinic's patient symptom lists, the Harvard and CDC study on serious side effects, and the SUSTAIN-6 retinopathy data. See our editorial and review policy and sourcing standards. Where evidence is still settling — as with the changing suicidal-ideation labeling and the unquantified rates of ileus and obstruction — we say so rather than overstating it.
Every clinical claim above is cited inline to a primary source. See how we review and our sourcing & fact-check standards.